Results demonstrated that TROY silencing impaired the cell cycle process (Supplementary Fig. 6C, 6D), the cell viability (Fig. 3D, Supplementary Fig. 6E) and increased the apoptotic index (Fig. 3E) of HCC cells in the presence of sorafenib, cisplatin, and 5-Fu. Here, TNFRSF19 is linked to hepatocellular carcinoma.